This article looks at the 14 Best Multibagger Penny Stocks to Buy Right Now.The Russell 2000 Index has hit fresh highs heading into 2026, signaling renewed interest in small companies. The index is already up by more than 13% for the year as market rotation from large-cap stocks gathers pace.The renewed focus on penny and small-cap stocks comes as investors rotate into higher-risk, higher-reward assets. The shift also underscores growing confidence in the broader economy and corporate sector, as they are ex ...

Core Insights - Arvinas, Inc. announced preclinical data for ARV-393 in combination with glofitamab, showing significant tumor growth inhibition in a model of diffuse large B-cell lymphoma (DLBCL) [1][3] - The company plans to initiate a Phase 1 clinical trial for this combination approach in 2026, aiming to provide a chemotherapy-free treatment option for patients with DLBCL [2][3] Group 1: Preclinical Data and Mechanism - The combination of ARV-393 (3 mg/kg) and glofitamab (0.15 mg/kg) achieved 81% tumor growth inhibition (TGI) with concomitant dosing and 91% TGI with sequential dosing, compared to 38% for ARV-393 alone and 36% for glofitamab alone [5] - At a higher dose of ARV-393 (6 mg/kg), the combination showed increased tumor regressions, with 10 out of 10 mice responding to concomitant dosing [5] - RNA sequencing indicated that ARV-393 upregulated CD20 expression and genes promoting interferon signaling, while downregulating proliferation-associated gene sets, contributing to the observed antitumor activity [5] Group 2: Clinical Development Plans - Arvinas is currently evaluating ARV-393 in a Phase 1 clinical trial for relapsed/refractory non-Hodgkin lymphoma and plans to share clinical data from this trial at a medical congress in 2026 [3] - The addition of a glofitamab combination cohort in the ongoing Phase 1 clinical trial of ARV-393 is planned for 2026 [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform, targeting various diseases including B-cell lymphomas [4][6] - The company is also advancing other investigational drugs targeting neurodegenerative disorders and mutated cancers [6]

Summary of ADC Therapeutics SA Lotus 7 Update Conference Call Company and Industry Overview - **Company**: ADC Therapeutics SA - **Industry**: Oncology, specifically focusing on therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Key Points and Arguments 1. **Clinical Trial Update**: ADC Therapeutics announced updated results from the LOTIS-7 clinical trial, focusing on the combination of Zynlonta and glofitamab for treating DLBCL [2][10] 2. **Zynlonta's Profile**: Zynlonta is positioned as a single-agent therapy for third-line plus DLBCL, with rapid, deep, and durable efficacy, and manageable safety [4][20] 3. **Market Opportunity**: The potential peak revenue for Zynlonta in DLBCL is estimated to be between $500 million and $800 million, with a broader potential reaching $600 million to $1 billion as it expands into earlier lines of therapy and indolent lymphomas [20][21] 4. **Efficacy Data**: The best overall response rate (ORR) in the LOTIS-7 trial was reported at 89.8%, with a complete response (CR) rate of 77.6% among 49 efficacy-available patients [11][12] 5. **Patient Demographics**: The median age of patients in the study was 70 years, with a range from 26 to 85 years, and a median of one prior line of therapy [12][14] 6. **Safety Profile**: Neutropenia was the most common treatment-emergent adverse event, occurring in 32.7% of patients, consistent with known profiles of the individual drugs [11][14][39] 7. **Combination Therapy Rationale**: The combination of Zynlonta and glofitamab is expected to provide additive or synergistic efficacy due to their complementary mechanisms of action [8][10] 8. **Regulatory Strategy**: ADC Therapeutics plans to submit for regulatory approval and compendia listing following positive results from ongoing trials, with updates expected in 2026 [22][23] Additional Important Information 1. **Treatment Landscape**: The DLBCL treatment landscape is evolving, with a current 60/40 split between complex therapies (e.g., CAR-T, bispecifics) and broadly accessible therapies (e.g., ADCs, monoclonal antibodies) [5][6] 2. **Future Catalysts**: Multiple data catalysts are expected in 2026, including updates from LOTIS-5 and LOTIS-7 trials, which could significantly impact Zynlonta's market potential [21][22] 3. **Durability of Responses**: Among patients achieving CR, 33 out of 38 maintained their response as of the data cutoff, indicating promising durability [11][19] 4. **Comparative Efficacy**: The trial showed strong efficacy in both relapsed (100% ORR, 91.6% CR) and primary refractory (80% ORR, 64% CR) patient populations [18][30] 5. **Enrollment Trajectory**: The company is on track to complete enrollment of 100 patients in the LOTIS-7 trial by the first half of 2026, with a focus on maintaining a balanced patient population [43] This summary encapsulates the critical insights from the ADC Therapeutics conference call, highlighting the company's strategic direction, clinical trial outcomes, and market potential in the oncology sector.

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

Core Viewpoint - Arvinas, Inc. is advancing its investigational drug ARV-393, a PROTAC designed to degrade the BCL6 protein, which is a significant driver of B-cell lymphomas, and will present preclinical data in December 2025 at the ASH Annual Meeting [1][3]. Group 1: About ARV-393 - ARV-393 targets the BCL6 protein, which plays a crucial role in B-cell lymphoma by repressing cell cycle checkpoints and apoptosis, making it a challenging target for traditional therapies [3]. - The drug is currently in a Phase 1 clinical trial for patients with non-Hodgkin lymphoma, indicating its potential therapeutic application in this area [3]. Group 2: About Arvinas - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize its PROTAC platform to selectively degrade disease-causing proteins [4]. - The company is also developing other investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-806 for mutated cancers, and vepdegestrant for ER+/HER2-breast cancer [4].

Financial Data and Key Metrics Changes - The company ended 2024 with $251 million in cash and cash equivalents, expected to fund operations into the second half of 2026 [24] - ZYNLONTA net product revenues for Q4 2024 were $16.4 million, slightly down from $16.6 million in Q4 2023, while full-year revenues were $69.3 million compared to $69.1 million in 2023 [25] - The net loss for Q4 2024 was $30.7 million, a significant improvement from a net loss of $85 million in Q4 2023 [26] - For the full year, the net loss was $157.8 million, down from $240.1 million in 2023 [26] - Non-GAAP operating expenses decreased by 15% year-over-year in Q4 2024, contributing to the reduced net loss [25][26] Business Line Data and Key Metrics Changes - ZYNLONTA maintained its position in the third-line-plus DLBCL market, achieving commercial brand profitability [9] - The company reported an overall response rate of 80% and a complete response rate of 50% in the LOTIS-5 trial, indicating strong efficacy [13] - Initial data from LOTIS-7 showed a best overall response rate of 94% and a complete response rate of 72% among relapsed or refractory DLBCL patients [14] Market Data and Key Metrics Changes - The company anticipates a peak revenue opportunity of $600 million to $1 billion in the US for ZYNLONTA, assuming regulatory approval and compendia listing [19][21] - The potential market opportunity for indolent lymphomas is estimated to be between $100 million and $200 million [22] Company Strategy and Development Direction - The company aims to expand the use of ZYNLONTA into earlier lines of DLBCL therapy through ongoing trials [13] - The strategy includes pursuing research collaborations to advance early-stage solid tumor pipelines [29] - The focus remains on hematology, with a disciplined capital allocation strategy to create value [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, highlighting the importance of upcoming data readouts in 2025 [30] - The competitive landscape is expected to evolve with the introduction of new therapies, but management believes ZYNLONTA will maintain its market position [76] Other Important Information - The company achieved a double-digit reduction in operating expenses for the second consecutive year [12] - Management emphasized the importance of regulatory strategies and compendia listings for future growth [50] Q&A Session Summary Question: Update on LOTIS-7 - The company has not disclosed the specific forum or timing for sharing LOTIS-7 data but is on track to enroll 40 patients in Q2 [42] Question: Impact of ADCETRIS Approval - Management believes the approval of ADCETRIS will have limited impact on ZYNLONTA's market share, as it is likely to replace older regimens rather than significantly affect current usage [44] Question: Regulatory Meetings for LOTIS-7 - Discussions with regulatory authorities are planned for the second half of the year once sufficient data is available [50] Question: Market Opportunity in Indolent Lymphoma - The peak opportunity for indolent lymphomas is estimated to be between $100 million and $200 million [51] Question: LOTIS-5 and LOTIS-7 Strategy - Both LOTIS-5 and LOTIS-7 are seen as complementary approaches to address different patient needs in the DLBCL market [56] Question: Importance of Upcoming Presentations - The upcoming presentations at AACR are expected to provide differentiating data on the company's ADC platforms [60] Question: Competitive Landscape for DLBCL - The introduction of bispecifics has taken about a third of the third-line-plus market, but ZYNLONTA has maintained consistent sales [75] Question: Compendia Listing and Market Penetration - Peak penetration for ZYNLONTA is typically achieved within the first two years post-approval or listing [86]